Want to see OVID full AI Analyst Report?
Top Page
Ovid Therapeutics
(NASDAQ:OVID)
Select Model
Select Model
Rating:53Neutral
Price Target:
$2.00
▼(-30.56% Downside)
Action:Reiterated
Date:08/18/26
The score is held down primarily by weak financial performance—sharp revenue decline, deep losses, and significant negative free cash flow—despite a relatively solid, low-leverage balance sheet. Technicals are a notable positive with price above key moving averages and positive MACD, while valuation remains constrained by negative earnings and no dividend support. Corporate events are mildly supportive but secondary versus the fundamental cash-burn risk.
Positive Factors
Low leverage
Low leverage gives Ovid more financial flexibility than many loss-making biotech companies, reducing near-term balance-sheet pressure and interest burden. The roughly $210M equity base relative to $12.7M of debt provides a stronger platform for funding development while management works to improve cash efficiency.
Negative Factors
Sharp revenue deterioration
The steep revenue decline materially weakens Ovid’s ability to support operations through internally generated funds or recurring commercial activity. Because the company relies primarily on collaborations and partnership-related payments, volatile or reduced revenue can make development planning and funding less predictable over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Low leverage gives Ovid more financial flexibility than many loss-making biotech companies, reducing near-term balance-sheet pressure and interest burden. The roughly $210M equity base relative to $12.7M of debt provides a stronger platform for funding development while management works to improve cash efficiency.
Read all positive factors
Ovid Therapeutics (OVID) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$421.84M
Dividend YieldN/A
Average Volume (3M)1.89M
Price to Earnings (P/E)―
Beta (1Y)2.08
Revenue Growth-76.20%
EPS Growth52.86%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.48
Shares Outstanding195,297,850
10 Day Avg. Volume2,032,993
30 Day Avg. Volume1,886,528
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)0.92
Price to Sales (P/S)16.57
P/FCF Ratio-3.14
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue269.52
Enterprise Value/Gross Profit269.52
Enterprise Value/Ebitda-11.97
Forecast
1Y Price Target
$6.50Price Target Upside125.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.37
Revenue Forecast (FY)$802.27K
Ovid Therapeutics Business Overview & Revenue Model
Company Description
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeuti...
How the Company Makes Money
As a clinical-stage biotechnology company, Ovid Therapeutics primarily generates revenue from collaboration-related and partnership-based payments rather than from ongoing product sales. Key sources can include (i) upfront payments received when e...
Ovid Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.58M | 7.25M | 566.00K | 392.00K | 1.50M | 208.38M |
| Gross Profit | 1.58M | 6.95M | 566.00K | 392.00K | 1.50M | 208.38M |
| EBITDA | -35.66M | -17.14M | -57.77M | -57.01M | -54.17M | 124.45M |
| Net Income | -34.49M | -17.41M | -26.43M | -52.34M | -54.17M | 122.83M |
Balance Sheet | ||||||
| Total Assets | 231.97M | 150.93M | 92.17M | 144.03M | 155.27M | 194.54M |
| Cash, Cash Equivalents and Short-Term Investments | 117.22M | 69.64M | 53.08M | 105.83M | 129.00M | 187.80M |
| Total Debt | 12.71M | 13.42M | 14.76M | 16.00M | 16.54M | 0.00 |
| Total Liabilities | 22.08M | 20.27M | 23.94M | 56.23M | 22.99M | 14.80M |
| Stockholders Equity | 209.89M | 130.66M | 68.23M | 87.80M | 132.27M | 179.75M |
Cash Flow | ||||||
| Free Cash Flow | -54.77M | -38.33M | -56.03M | -45.92M | -56.65M | 118.42M |
| Operating Cash Flow | -54.77M | -38.33M | -55.96M | -45.78M | -55.23M | 118.61M |
| Investing Cash Flow | -147.80M | -49.85M | 54.59M | -2.58M | -87.88M | -1.82M |
| Financing Cash Flow | 185.78M | 75.21M | 622.00K | 30.54M | 180.66K | 904.08K |
Ovid Therapeutics Technical Analysis
Negative
2.88
Price Trends
2.58
Negative
2.52
Negative
2.34
Negative
Market Momentum
-0.08
Negative
39.52
Neutral
43.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OVID, the sentiment is Negative. The current price of 2.88 is above the 20-day moving average (MA) of 2.35, above the 50-day MA of 2.58, and above the 200-day MA of 2.34, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 39.52 is Neutral, neither overbought nor oversold. The STOCH value of 43.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OVID.
Ovid Therapeutics Risk Analysis
Ovid Therapeutics disclosed 58 risk factors in its most recent earnings report. Ovid Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ovid Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $421.84M | -4.50 | -23.64% | ― | -76.20% | 52.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $209.22M | -0.90 | -87.95% | ― | -100.00% | 14.08% | |
46 Neutral | $221.86M | -3.35 | -42.80% | ― | ― | 59.89% | |
46 Neutral | $299.48M | -0.62 | 187.62% | ― | -8.79% | -195.46% | |
45 Neutral | $288.69M | -2.73 | 1147.63% | ― | -36.09% | 24.84% | |
44 Neutral | $43.50M | -1.21 | -171.19% | ― | ― | 83.55% |
* Healthcare Sector Average
OVID
Ovid Therapeutics
2.16
0.56
35.00%
IRD
Opus Genetics
3.47
1.47
73.50%
ZNTL
Zentalis Pharmaceuticals
2.21
0.49
28.49%
IKT
Inhibikase Therapeutics
1.59
0.03
1.92%
SRZN
Surrozen
25.48
11.55
82.91%
BMEA
Biomea Fusion
0.60
-0.82
-57.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.